Immunoadsorption as a Tool for the Immunomodulation of the Humoral and Cellular Immune System in Autoimmune Disease

Braun, Norbert; Risler, T.

doi:10.1046/j.1526-0968.1999.00155.x

Cited by 38 publications

(30 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anticoagulation was achieved in addition to ACD-A at a ratio of 12:1 (WB:ACD-A) with a 2,500 IU sodium heparin bolus and a continuous infusion of 1,000 IU sodium heparin/h. 9 We performed the IA with a ratio of 15:1 (WB:ACD-A) and added 1,000 U heparin/h. Handschel et al observed clumping or granularity in the buffy coats at a ratio of 20:1/25:25 (WB:ACD-A).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Spectra Optia apheresis system: experience with secondary plasma devices

Rummler¹,

Volkholz²,

Steinke³

et al. 2017

IJCTM

View full text Add to dashboard Cite

Abstract:Performing clinical procedures and optimal management of Spectra Optia in combination with secondary plasma devices (SPDs) have not been described in the literature. To contribute to this topic, we examined 300 data log files from patients treated with the Spectra Optia from November 2015 until October 2016. Of these 300 procedures, 149 secondary plasma treatments were conducted in 13 patients (76 immunoadsorption [IA] and 73 lipoprotein apheresis [LA]). Nine patients had IA due to transplantation and autoimmune diseases. Four patients were treated with LA after heart transplantation. Of the procedures, 62% were performed using peripheral venous access, even in patients with a low inlet blood flow. A central catheter was required only in 15% cases, and an arteriovenous fistula in 23% of the procedures. Anticoagulation management differed in both procedures. The LA procedures required a higher amount of citrate as they were performed using only citrate. The IA procedures required less citrate because a mixture of citrate and heparin was used. We did not observe clotting or bleeding, regardless of heparin use. Due to strict calcium management, no patient showed signs of hypocalcemia. Despite our apheresis management, four procedures had to be canceled preliminarily due to patient complications. The targeted substances could be reduced significantly: lipoprotein (a) (Lpa) level by 68% (76%-45%), low-density lipoprotein-cholesterol by 57% (64%-37%), and IgG from 6.6 (1.09-21.0) to 2.61 (0.33-14.7) g/l. The Cobe could be replaced by the Optia system effectively. The Optia has a high plasma extraction efficiency, which allows SPD procedures with peripheral venous access and moderate inlet flow rates.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A high amount of IgG allows a maximum plasma flow of 35 ml/ min; a low IgG level at the end of IA cycles requires a plasma flow of 10-20 ml/min. 9 According to our standard operating procedures, we fixed the target PV for autoantibodies to 2.2 times and alloantibodies to 2.5 times the PV.…”

Section: Patientsmentioning

confidence: 99%

Spectra Optia apheresis system: experience with secondary plasma devices

Rummler¹,

Volkholz²,

Steinke³

et al. 2017

IJCTM

View full text Add to dashboard Cite

show abstract

“…Therefore, removal of autoantibodies from the circu lation is an effective way to treat patients with such diseases and myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, and others. Immunoadsorbtion column systems for selective plasma perfusion or hemoperfusion available for the clinical use are presented in Table 3 [32][33][34][35][36][37][38][39].…”

Section: селективные гемосорбентыmentioning

confidence: 99%

“…The system is used for treatment of patients with myasthenia and other immunopathological disorders [36].…”

Section: селективные гемосорбентыmentioning

confidence: 99%

Sorbents for Extracorporeal Removal of Toxic Substances and Molecules with Adverse Biological Activity (Review)

Morozov¹,

Bessonov²,

Нуждина³

et al. 2016

rmt

View full text Add to dashboard Cite

“…Recent findings show that extracorporeal removal of immunoglobulins by adsorption techniques might also impact on T cell mediated immune responses in addition to the immunoglobulin reducing effect. 10,11 Yet, the modulatory effect of plasma exchange on the immune system does not persist over time. Hence, the frequency of apheresis treatment needs to be determined individually according to the underlying disease, the patient's improvement and the rebound of pathogenic factors.…”

Section: Introductionmentioning

confidence: 99%

Plasmapheresis for neuroinflammatory disorders

Schröder

Linker

Gold

2010

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Nowadays, therapeutic plasma exchange (PE) is the most common apheresis procedure. Plasma is separated from corpuscular blood constitutents and replaced with a substitution fluid. Thus, PE is a non‐specific treatment modality. Its therapeutic effect is based on the removal of circulating, pathogenic immune factors, including autoantibodies. To date, PE is well established for several immune mediated neurological disorders. Whilst the first experience was acquired in acute life‐threatening conditions, such as the treatment of Guillain–Barré syndrome or myasthenic crisis, therapeutic success was later achieved in other chronic autoimmune diseases; PE was applied successfully in chronic inflammatory demyelinating polyneuropathy, paraproteinaemic polyneuropathy, stiff‐person syndrome and might also be tried in autoimmune diseases of paraneoplastic origin. From a novel aspect, PE was also established as an escalation therapy for steroid unresponsive relapses of multiple sclerosis, and thus has gained even more widespread attention. Humoral disease mechanisms dominate even more in neuromyelitis optica, as a subtype of MS, and usually respond to PE. Adding to its increasing application in clinical practice, the procedure is usually well tolerated. Possible adverse reactions of PE arise from the large‐size vascular access site, the use of replacement fluids and the need for anticoagulation. (Clin. Exp. Neuroimmunol. doi: 10.1111/j.1759‐1961.2010.0010.x, 2010)

show abstract

Immunoadsorption as a Tool for the Immunomodulation of the Humoral and Cellular Immune System in Autoimmune Disease

Cited by 38 publications

References 18 publications

Spectra Optia apheresis system: experience with secondary plasma devices

Spectra Optia apheresis system: experience with secondary plasma devices

Sorbents for Extracorporeal Removal of Toxic Substances and Molecules with Adverse Biological Activity (Review)

Plasmapheresis for neuroinflammatory disorders

Contact Info

Product

Resources

About